drugset / Trial / NCT01841333
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Phase 2
Completed
31 enrolled
University of Colorado, Denver
The Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial will test whether the Hedgehog signaling pathway inhibitor PF-04449913 can decrease disease relapse in high-risk patients with acute myeloid leukemia after donor stem cell transplant.
Timeline
- Start
- 2013-04-29
- Primary completion
- 2019-05-08
- Completion
- 2020-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glasdegib | Small molecule | 100 mg | Oral |